Frequently Asked Questions about Day One Biopharmaceuticals, Inc. (DAWN)

Name: Day One Biopharmaceuticals, Inc. (DAWN) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Day One Biopharmaceuticals, Inc. (DAWN) do?

Accepted Answer

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that...

Question 2

Is Day One Biopharmaceuticals, Inc. (DAWN) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of DAWN reveals an Altman Z-Score of 18.73 and a Piotroski F-Score of 3/9. These metrics, combined with its 5-year revenue trend ($0.16B most recent), help investors decide if DAWN fits their risk profile.

Question 3

What is the current P/E ratio for DAWN?

Accepted Answer

As of the latest trading session, Day One Biopharmaceuticals, Inc. (DAWN) has a trailing P/E ratio of -20.64.

Question 4

Who is the CEO of Day One Biopharmaceuticals, Inc.?

Accepted Answer

The current Chief Executive Officer of Day One Biopharmaceuticals, Inc. is Jeremy Bender.

Question 5

What was DAWN's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Day One Biopharmaceuticals, Inc. reported annual revenues of $0.16B (2025), $0.13B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does DAWN pay a dividend?

Accepted Answer

Day One Biopharmaceuticals, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does DAWN have?

Accepted Answer

In its latest reporting period, Day One Biopharmaceuticals, Inc. generated $-0.10B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of Day One Biopharmaceuticals, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Day One Biopharmaceuticals, Inc. (DAWN) is currently 5.02.

Question 9

What is the Price-to-Sales (P/S) ratio of DAWN?

Accepted Answer

Based on trailing twelve-month data, Day One Biopharmaceuticals, Inc. (DAWN) trades at a Price-to-Sales (P/S) ratio of 13.99.

Question 10

What is Day One Biopharmaceuticals, Inc.'s Return on Equity (ROE)?

Accepted Answer

Day One Biopharmaceuticals, Inc. (DAWN) has a Return on Equity (ROE) of -23.43%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	-103.8M	44.4M	-320K	-104.1M	-148.5M
2024-12	-78.1M	48.3M	-2.2M	-80.3M	-128.5M
2023-12	-146.9M	39.3M	-3.2M	-150.1M	-189.4M
2022-12	-109.9M	27.2M	-26K	-109.9M	-137.1M
2021-12	-48.5M	13.3M	-8M	-56.5M	-69.9M

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	-103.8M	44.4M	-320K	-104.1M	-148.5M
2024-12	-78.1M	48.3M	-2.2M	-80.3M	-128.5M
2023-12	-146.9M	39.3M	-3.2M	-150.1M	-189.4M
2022-12	-109.9M	27.2M	-26K	-109.9M	-137.1M
2021-12	-48.5M	13.3M	-8M	-56.5M	-69.9M